Any active acute or chronic or uncontrolled infection Other acute or chronic medical or psychiatric condition Active (acute or chronic) or uncontrolled severe infections Have active (acute or chronic) or uncontrolled severe infections Acute or chronic skin and/or microvascular disorders Acute urinary tract infection. Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within days prior to study enrollment Documented malabsorptive syndromes including enteropathies, gastroenteritis (acute or chronic) or diarrhea (acute or chronic) Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded Other severe acute or chronic medical condition Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within days prior to randomization Acute or chronic infections requiring systemic therapy, including, among others: Systemic rheumatic or autoimmune diseases or acute or chronic infections Acute VOC ending days prior to first dosing Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled) Patients must not have received any prior systemic therapy for ALL, except for the acute management of hyperleukocytosis or acute symptoms (e.g., corticosteroids, cytarabine, etc.) Significant acute or chronic infections requiring systemic therapy Acute or chronic skin disorders that would interfere with subcutaneous injection of the vaccine or subsequent assessment of potential skin reactions Acute, severe infection (e.g., sepsis and opportunistic infections), or active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., herpes zoster). Any acute or chronic psychiatric problems Subject has any acute infection that requires specific therapy; acute therapy must have been completed within seven days prior to study enrollment Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within days prior to study enrollment Subjects with any acute infection or severe or uncontrolled that requires systematic antibiotic therapy; acute therapy must have been completed at least seven days prior to study enrollment Have active, acute, or chronic clinically significant infections. Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded Evidence of active acute or chronic infection Ongoing acute or chronic inflammatory skin disease. Subjects with an acute gastrointestinal ulcer Acute or chronic infections requiring systemic therapy, including, among others: Subjects have any acute infection that requires specific therapy. Acute therapy must have been completed within seven days prior to study enrollment. Prostate abscess, chronic or acute prostatitis, or neurogenic bladder Active (acute or chronic) or uncontrolled severe infections. Active (acute or chronic) or uncontrolled severe infections Significant acute or chronic infections Acute infections requiring parenteral therapy Acute unresolved Urinary Tract Infection (UTI) History of acute urinary retention within the last months Have malabsorptive syndromes, enteropathies, gastroenteritis (acute or chronic), or diarrhea (acute or chronic). Ongoing acute or chronic inflammatory skin disease. Active (acute or chronic) or uncontrolled severe infections (not responding to antibiotics), including acute pelvic inflammatory disease Electrocardiogram showing no acute ischemic changes Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded Active (acute or chronic) or uncontrolled severe infection Active (acute or chronic) or uncontrolled severe infections hepatitis Subjects with acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy; acute therapy must have been completed more than days prior to study treatment No evidence of acute infection Subject has any acute infection that requires specific therapy; acute therapy must have been completed within seven days prior to study enrollment Significant acute or chronic infections, including: Patients with acute or chronic infection Acute or chronic viral, bacterial immune or other disease associated with abnormal immune function Ongoing acute or chronic inflammatory skin disease. Procedures that occur during acute hospitalization. Acute nephritis Has an Acute Physiology and Chronic Health Evaluation (APACHE) II score < Active (acute or chronic) or uncontrolled severe infections Have active, acute, or chronic clinically significant infections or bleeding. Skin toxicity including but not limited to erythema, rash, ulceration, and open wound that is still clinically present and considered as acute or chronic. Acute viral hepatitis or history of chronic or acute HBV, HCV, HAV, HDV, HEV Acute or chronic skin disorders that will interfere with subcutaneous injection of the vaccine or subsequent assessment of potential skin reactions History of functionally limiting chronic or acute cardiac, pulmonary, or neuromuscular disease Sepsis and/or acute, chronic, or ongoing infections that are currently being treated with systemic antimicrobials Acute medical conditions, such as acute flare-up of joint condition or infection Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled) Participants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis) Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within weeks before Segment B enrollment Acute febrile illness Acute or chronic respiratory disease Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha- antitrypsin deficiency Any medical contradiction to use of a Mirena IUD, including:\r\n* Pregnancy (a pregnancy test is required prior to study entry)\r\n* Known uterine anomaly that distorts the shape of the uterine cavity \r\n* Acute pelvic inflammatory disease\r\n* Postpartum endometritis or endometrial infection\r\n* Known or suspected uterine or cervical neoplasia\r\n* Known history or suspected breast cancer or other progestin-sensitive cancer\r\n* Uterine bleeding of unknown etiology\r\n* Untreated acute cervicitis, vaginitis, or other lower genital tract infections\r\n* Acute liver disease or liver tumor (benign or malignant) Use of systemic antibacterials, antifungals or antivirals for the treatment of acute clinically significant infection within weeks of first veledimex dose. Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile prior to Ad-RTS-hIL- injection; only prophylactic antibiotic use is permitted perioperatively. acute respiratory failure, acute infection without septic shock, acute myocarditis or acute systemic infection and Patients with acute serious illnesses at the discretion of the primary investigator Acute prostatitis within the last months Patients suffering from active acute or chronic prostatitis Have an acute or a chronic hematoma and/or acute ecchymosis of the thyroid; Symptomatic acute prostatitis Documented acute prostatitis or urinary tract infections Not in acute crisis